Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Sunday, Molecular Partners And Orano Med Present Preclinical Data On Mesothelin-Targeting Radio-DARPin MP0726 At SNMMI 2025

Author: Benzinga Newsdesk | June 23, 2025 02:10am

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano Med
Promising tumor accumulation and attractive biodistribution shown in vivo, selective binding to membrane-bound MSLN with positive tumor to kidney ratio

Posted In: MOLN